Archives

Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.

Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.

In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.

Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported